Thrombosis and Hemostasis Research
Thrombosis is a crucial hemostatic process for maintaining blood volume (hemostasis) following injury, yet aberrant thrombosis can trigger pathological conditions including myocardial infarction and stroke. Therefore the initiation of thrombosis is tightly controlled under physiological conditions.
Thrombosis and Hemostasis Research Products Targets
- PI 3-kinase (22)
- Cell Adhesion Molecule (21)
- Others (7)
- Cyclooxygenase (24)
- PPARγ (16)
- PPARδ (5)
- PPARα (7)
- NK2 Receptor (7)
- NK1 Receptor (15)
- NK3 Receptor (5)
- Chemokine CXC Receptor (9)
- Chemokine CC Receptor (13)
- NO donors and precursors (9)
- nNOS (5)
- iNOS (11)
- eNOS (1)
- Purinergic (P2Y) Receptor (31)
- Protease-Activated Receptor (23)
- Phospholipase (16)
- Prostanoid Receptor (24)
- Phosphodiesterase (34)
Products for Thrombosis and Hemostasis Research - Page 27
- Cat.No. Product Name Information/Activity
-
BCC7268
nTZDpa
118414-59-8
-
BCC2278
Pioglitazone HCl
Pioglitazone hydrochloride is a potent and selective PPARγ agonist with EC50s of 0.93 and 0.99 μM for human and mouse PPARγ, respectively.
-
BCC7321
15-deoxy-Δ-12,14-Prostaglandin J2
15-Deoxy-Δ-12,14-prostaglandin J2 (15d-PGJ2) is a cyclopentenone prostaglandin and a metabolite of PGD2. 15-Deoxy-Δ-12,14-prostaglandin J2 is a selective PPARγ (EC50 of 2 µM) and a covalent PPARδ agonist. 15-Deoxy-Δ-12,14-prostaglandin J2 promotes efficient differentiation of C3H10T1/2 fibroblasts to adipocytes with an EC50 of 7 μM.
-
BCC2264
Rosiglitazone
Rosiglitazone (BRL 49653) is a selective PPARγ activator with EC50s of 30 nM, 100 nM and 60 nM for PPARγ1, PPARγ2, and PPARγ, respectively.
-
BCC7751
S26948
353280-43-0
-
BCC3863
Telmisattan
Telmisartan is a potent, long lasting antagonist of angiotensin II type 1 receptor (AT1), selectively inhibiting the binding of 125I-AngII to AT1 receptors with IC50 of 9.2 nM.
-
BCC2016
Troglitazone
Troglitazone is a PPARγ agonist, with EC50s of 550 nM and 780 nM for human and murine PPARγ receptor, respectively.
-
BCC7022
BADGE
1675-54-3
-
BCC2260
GW9662
GW9662 is a potent and selective PPARγ antagonist with an IC50 of 3.3 nM, showing 10 and 1000-fold selectivity over PPARα and PPARδ, respectively.
-
BCC7243
SR 202
Mifobate (SR-202) is a potent and specific PPARγ antagonist. Mifobate (SR-202) selectively inhibits Thiazolidinedione (TZD)-induced PPARγ transcriptional activity (IC50=140 μM). Mifobate (SR-202) does not affect basal or ligand-stimulated transcriptional activity of PPARα, PPARβ, or the farnesoid X receptor (FXR). Mifobate (SR-202) shows antiobesity and antidiabetic effects.
